Recent Episodes
Watch recent episodes on
PTV News Review
Scroll Left
Scroll Right
AusBioTech: Dr Anna Lavelle




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: AusBioTech: Dr Anna Lavelle
Released on: December 08, 2010. © PharmaTelevision Ltd
Visitors: You are watching a 5 minute preview.
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
  • Summary
  • Transcript
  • Participants
  • Company
In this episode of PharmaTelevision News Review, Fintan Walton talks to Dr Anna Lavelle, CEO of AusBioTech.
Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.
Key issues facing AusBiotech
Fintan Walton:
Hello and welcome to PharmaTelevision News Review here at AusBiotech in Melbourne, in October 2010. On this show I have Anna Lavelle, who is CEO of AusBiotech, welcome to the show.
Anna Lavelle:
Thank you Fintan.
Fintan Walton:
It's good to meet you again Anna Lavelle, because every year I come here to talk about AusBiotech and things changed in Australia, things are changing as they always do. Anna for you and your organizations what are the key issues that is facing AusBiotech other than just simply you know the lack of capital and so forth, we will come on to that, what are the key issues?
Anna Lavelle:
So I know last year we focused on the lack of capital, because the global financial crisis was really hitting people everywhere, but certainly here in Australia and one of the frustrations here is of course that we have trillions of dollars in super innovation funds but they going into US venture funds versus Australian venture funds so you can imagine that the local companies here see that as an issue as well as that on the policy front you know we have concerns that outside of Australia, but certainly there's been some local activity on the gene patent area and also on taxation the credit refundable credit that we've been trying to negotiate with the federal government for the last two-years now.
Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.
Fintan Walton
Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).
Anna Lavelle
Chief Executive Officer
Anna Lavelle was appointed inaugural CEO and Executive Director of AusBiotech in June 2005. She is also a member of the Pharmaceutical Industry Council. Previously Dr Anna Lavelle joined the Australian Red Cross Blood Service (ARCBS) in 1998 as Director responsible for Strategic Planning and Business Development. In 2002, Dr Anna Lavelle was appointed Director of Intellectual Capital, in which role she was responsible for management of the national research and development programme. Before joining ARCBS, Dr Anna Lavelle had commenced employment as an academic at Monash University, Melbourne, after having gained her PhD in Genetics from the University of Melbourne.
PharmaVentures
PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.
AusBiotech
AusBiotech is Australia's biotechnology industry organization, which represents over 3,000 members, covering the human health, agricultural, medical device, bioinformatics, environmental and industrial sectors in biotechnology. AusBiotech is dedicated to the development, growth and prosperity of the Australian biotechnology industry, by providing initiatives to drive sustainability and growth, outreach and access to markets, and representation and support for members nationally and around the world. AusBiotech has representation in each Australian state providing a national network to support members and promote the commercialization of Australian bioscience in the national and international marketplaces. The structure is a not-for-profit limited guarantee company managed by a Board elected by members in line with its constitution. AusBiotech membership base includes biotechnology companies, ranging from start-ups to mature multinationals, research institutes and universities, specialist service professionals, corporate, institutional, individual and student members from Australia and overseas. In assessing the current needs and issues faced by Australia's core biotechnology companies, AusBiotech's Strategic Business Plan addresses the requirements to build a favorable environment to enable companies to grow, help them globalize and position Australia as a significant biotechnology industry for increasing international investment and interest.